Business Description
Achilles Therapeutics PLC
ISIN : US00449L1026
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 26.67 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -29.6 | |||||
3-Year EPS without NRI Growth Rate | -28.7 | |||||
3-Year FCF Growth Rate | -10.7 | |||||
3-Year Book Growth Rate | -9.4 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.6 | |||||
9-Day RSI | 48.78 | |||||
14-Day RSI | 48.24 | |||||
12-1 Month Momentum % | -25.77 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.63 | |||||
Quick Ratio | 9.63 | |||||
Cash Ratio | 8.23 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 6.74 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -41.03 | |||||
ROA % | -36.28 | |||||
ROIC % | -235.13 | |||||
ROC (Joel Greenblatt) % | -321.14 | |||||
ROCE % | -44.25 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.3 | |||||
Price-to-Tangible-Book | 0.3 | |||||
EV-to-EBIT | 0.98 | |||||
EV-to-EBITDA | 1.01 | |||||
EV-to-FCF | 3.8 | |||||
Price-to-Net-Current-Asset-Value | 0.33 | |||||
Price-to-Net-Cash | 0.4 | |||||
Earnings Yield (Greenblatt) % | 102.04 | |||||
FCF Yield % | -46.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Achilles Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.48 | ||
Beta | -0.03 | ||
Volatility % | 68.68 | ||
14-Day RSI | 48.24 | ||
14-Day ATR (€) | 0.024653 | ||
20-Day SMA (€) | 0.79725 | ||
12-1 Month Momentum % | -25.77 | ||
52-Week Range (€) | 0.68 - 1.44 | ||
Shares Outstanding (Mil) | 42.7 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Achilles Therapeutics PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Achilles Therapeutics PLC Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Achilles Therapeutics PLC Frequently Asked Questions
What is Achilles Therapeutics PLC(STU:698)'s stock price today?
When is next earnings date of Achilles Therapeutics PLC(STU:698)?
Does Achilles Therapeutics PLC(STU:698) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |